We follow a ‘growth at a reasonable price (GARP) investing style’ since it combines the best of both worlds. We have identified themes that provide secular growth opportunities such as private banks, unorganised to organised, speciality chemicals, manufacturing in India, and technology/digital.

Canara Robeco has launched its Canara Robeco Focused Equity Fund and is currently opened for subscription. Read onto find out more about it.

Following the global trend of medication shifting from allopathy to herbal therapy in veterinary, Hester Biosciences announced on Saturday that it has embarked on a journey to produce research-based herbal products for livestock and poultry.  

How should investors evaluate a company while considering an investing in the company's stock? Read on to find out more.

SEBI registered investment advisers (RIAs) do promote direct plans in mutual funds a lot. So, does it make sense to invest in direct plans via them? Let’s find out.

The most important market moving news for the week ending April 23, 2021.

Caplin Steriles Limited, a subsidiary company of Caplin Point Laboratories Limited announced this morning that it has been granted approval from USFDA for its abbreviated new drug application (ANDA) Prochlorperazine Edisylate injection USP, 10 mg/2 ml (5 mg/ml) vials presentations.

Considering the most important assumption in technical analysis i.e. 'history tends to repeat itself’, we believe that a similar quantum of moves is on cards.

Tata Elxsi is turning out to be a star performer from the pack of Tata Group stocks. The stock jumped more than eight per cent on Friday, trading at Rs 3,291.55 per share.   

On Friday, Alembic Pharmaceuticals informed the exchanges that it has received final approval from US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA), Doxepin Hydrochloride capsules, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg & 100 mg.